
US cost-effectiveness of saxagliptin in type 2 diabetes mellitus

Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert M

Record Status

This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert M. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. *American Journal of Pharmacy Benefits* 2012; 4(1): 20-28

Original Paper URL

<http://www.ajpblive.com/login/15135>

Indexing Status

Subject indexing assigned by CRD

MeSH

Humans; Diabetes Mellitus, Type 2; Adamantane; Dipeptidyl-Peptidase IV Inhibitors

AccessionNumber

22012018472

Date bibliographic record published

14/01/2013